로딩 중…
StockDiggingStockDigging

Labcorp Holdings Inc.

LH· NYSE
$307.60-0.52%
2026-08-03

Financials

Valuation Metrics

Labcorp Holdings Inc.'s Market Cap is $25.22B. At end of 2025 it was $20.65B. Ranked #524 of 3,112 in US market (top 17%), #369 of 1,667 on NYSE (top 22%), #35 of 206 in Health Care Equipment & Services (top 17%) by Market Cap.

Investment Metrics(as of 2026-08-03)

MetricValue
Size
Market Cap$25.22B
Revenue$14.14B
Net Income$942M
Total Assets$19.09B
Net Assets$8.73B
Employees61,770
Value
P/E26.79x
P/B2.89x
PEG0.88x
P/S1.78x
EV/EBITDA15.26x
FCF Yield5.49%
Profitability
ROE10.79%
ROA4.93%
Op. Margin11.03%
Revenue Growth5.75%
Earnings Growth30.55%
Financial Health
Debt Ratio118.48%
Total Debt$7.24B
FCF$1.38B
Cash$981M
Current Ratio1.73x
Net Debt/EBITDA3.03x
Dividend
Div. Yield0.95%
Div. Growth-0.16%
Performance
1Y Return18.55%
1M Return7.19%
From 52W High-2.69%
1Y MDD-15.22%
Trading
Volume549,250 shares
Trading Value$170M
Per Share
EPS$10.62
BPS$104.48

Company Info

CEO Mr. Adam H. Schechter
Employees 61,770
HQ Burlington, United States

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company was founded in 1995 and is headquartered in Burlington, North Carolina.